JBM  Vol.7 No.5 , May 2019
EBV-Associated Post-Transplantation B-Cell Lymphoproliferative Disorder in Patient after Allogenic Stem Cell Transplantation
Epstein-Barr virus (EBV)-associated B-cell post-transplantation lymphoproliferative disorder (PTLD) is a severe complication following solid-organ transplantation (SOT) and allogeneic hematopoietic stem cell transplantation (HSCT). We present a case of a 15-year-old male developing a monomorphic B-cell PTLD after receiving an allogenic stem cell transplant for acute acute myeloid leukemia. A diagnostic lymph node biopsy revealed monomorphic type, B cell phenotype, associated with Epstein-Barr virus, consistent with post-transplant lymphoproliferative disorder (PTLD). The morbidity and mortality of PTLD are high, and there is no standard protocol for treatment of PTLD. To prevent the occurrence of PTLD and early intervention are important for the prognosis of patients.
Cite this paper: Tang, L. and Li, Y. (2019) EBV-Associated Post-Transplantation B-Cell Lymphoproliferative Disorder in Patient after Allogenic Stem Cell Transplantation. Journal of Biosciences and Medicines, 7, 11-15. doi: 10.4236/jbm.2019.75003.

[1]   Kasahara, H., Mori, T., Kato, J., et al. (2015) Post-Transplant Lymphoproliferative Disorder of the Adrenal Gland after Allogeneic Hematopoietic Stem Cell Transplantation: Report of Two Cases and Literature Review. Transpl Infect Dis., 17, 909-914.

[2]   San-Juan, R., Comoli, P., Caillard, S., et al. (2014) Epstein-Barr Vi-rus-Related Post-Transplant Lymphoproliferative Disorder in Solid Organ Transplant Recipients. Clin Microbiol Infect., 20, 109-118.

[3]   Green, M. and Michaels, M.G. (2013) Epstein-Barr Virus Infection and Posttransplant Lymphoproliferative Disorder. Am J Transplant, 13, 41-54.

[4]   Choi, J.H., Park, B.B., Suh, C., et al. (2010) Clinical Characteristics of Monomorphic Post-Transplant Lymphoproliferative Disorders. J Korean Med Sci, 25, 523-526.

[5]   Reddy, N., Rezvani, K., Barrett, A.J., et al. (2011) Strategies to Prevent EBV Reactivation and Posttransplant Lymphoproliferative Disorders (PTLD) after Allogeneic Stem Cell Transplantation in High-Risk Patients. Biol Blood Marrow Transplant, 17, 591-597.

[6]   Nijland, M.L., Kersten, M.J., Pals, S.T., et al. (2016) Epstein-Barr Virus-Positive Posttransplant Lymphoproliferative Disease after Solid Organ Transplantation: Pathogenesis, Clinical Manifestations, Diagnosis, and Management. Transplant Direct, 2, e48.

[7]   Swerdlow, S.H., Campo, E., Pileri, S.A., et al. (2016) The 2016 Revision of the World Health Organization Classification of Lymphoid Neoplasms. Blood., 127, 2375-2390.

[8]   Selvanathan, A., Ellaway, C., Wilson, C., et al. (2018) Effectiveness of Early Hematopoietic Stem Cell Transplantation in Preventing Neurocognitive Decline in Mucopolysaccharidosis Type II: A Case Series. JIMD Rep., 41, 81-89.

[9]   Al-Mansour, Z., Nelson, B.P. and Evens, A.M. (2013) Post-Transplant Lymphoproliferative Disease (PTLD): Risk Factors, Diagnosis, and Current Treatment Strategies. Curr Hematol Malig Rep., 8, 173-183.

[10]   Singavi, A.K., Harrington, A.M. and Fenske, T.S. (2015) Post-Transplant Lymphoproliferative Disorders. Cancer Treat Res., 165, 305-327.